Abstract
In the industry-sponsored, randomized TARGET trial, researchers compared the effects of the glycoprotein IIb/IIIa inhibitors abciximab and tirofiban in 4809 patients before intracoronary stenting (for 6-month results, see Journal Watch Cardiology Sep 20 2002). Now, in a subanalysis, researchers compared abciximab and tirofiban recipients for thrombocytopenia and associated outcomes. Thrombocytopenia occurred in 2% of …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
